0 Comments
Market Scenario
The MRFR's Lupus Market analysis expected the market to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 1.48 billion in 2017 and is projected to grow at a CAGR of 11.2% over the forecast period. Lupus is a systemic autoimmune disease that causes inflammation throughout the body. In patients with lupus, the immune system attacks healthy cells and tissues of the body which can result in damage to many parts of the body including the skin, joints, kidney, heart, lungs, blood vessels, and brain. The factors such as the rising prevalence of lupus, ongoing medical advancements in the treatment of systemic lupus erythematosus, increasing research and development activities are expected to drive market growth during the forecast period. According to the Lupus Foundation of America, about 1.5 million Americans have a form of lupus, and about 16,000 new cases are reported each year in the Americas. Despite the drivers, the factors such as strict government regulation and increasing prices of lupus drugs may hamper the market growth over the assessment period. Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6636 Currently, a large number of companies are present in the lupus market. The prominent market players are involved in the development of new products and product launches. For instance, in July 2017, GlaxoSmithKline received FDA approval for a new self-injectable formulation of Benlysta for the treatment of adult patients with systemic lupus erythematosus. Segmentation The Global Lupus Market has been segmented into types, treatment, and end user. The global market, on the basis of type, has been segmented into systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus erythematosus, and neonatal lupus. The systemic lupus erythematosus segment is expected to hold the largest market share owing to the growing prevalence and increasing drug development in recent years. On the basis of treatment, the market has been segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial drugs, corticosteroids, immunosuppressants, biologics, and other. On the basis of end user, the market has been segmented into hospital & clinics, diagnostic laboratories, and others. The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The lupus market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European lupus market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The lupus market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The lupus market in the Middle East & Africa has been segmented into the Middle East and Africa. Key Players Aurinia Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Sanofi, Lycera Corporation, Merck KGaA, and Eli Lily and Company are some of the key players in the global lupus market. Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/lupus-market-6636 About Us: Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Contact Us: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India Phone: +1 646 845 9312 Email: [email protected] Market Scenario
The global respiratory care devices market size is expected to register a significant growth at 10.1% CAGR during the forecast period (2018–2023). The respiratory care devices are used for treatment, assessment, diagnosis, and care of patients suffering from cardiopulmonary devices. Respiratory care devices are used in the treatment of lung diseases such as chronic bronchitis, tuberculosis, acute and chronic pulmonary diseases, asthma, and others. With the growing age, the function of lungs starts to decline and hence the respiratory system undergoes various physiological, functional and immunological changes. The market growth is due to the rising incidences of chronic pulmonary diseases, asthma, and others. These devices can be used in hospitals and in-home care settings as they have developed from stationary to portable ones. Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6517 Factors such as the increasing frequency of respiratory diseases, increasing geriatric population, urbanization, and its adverse effects, and changes in the environment and lifestyle boosts the growth of the market. The growing demand for point-of-care diagnostic devices in developing regions is anticipated to provide new opportunities for players in the respiratory care devices market. The lack of awareness about respiratory problems, intense competition, and the cost associated with the device and the respiratory surgery hamper the growth of the market. Segmentation The global respiratory care devices market has been segmented on the basis of therapeutic devices, monitoring devices, diagnostic devices, accessories and consumables, application, and end-users. On the basis of therapeutic devices, the market has been classified as pap devices, masks, ventilators, nebulizers, humidifiers, oxygen concentrators, inhalers, reusable resuscitators, nitric oxide delivery units, and oxygen hoods. On the basis of monitoring devices, the market has been classified as pulse oximeters, pulse oximeter sensors, pulse oximeter equipment, capnographs, and gas analyzers. On the basis of diagnostic devices, the market has been classified as spirometers, polysomnography (PSG) devices, peak flow meters, and other diagnostic devices. On the basis of accessories and consumables, the market has been classified as disposable masks, disposable resuscitators, tracheostomy tubes, nasal cannulas, and other consumables and accessories. On the basis of application, the market has been classified as chronic obstructive pulmonary disease (COPD), sleep apnea, asthma, infectious diseases, and other diseases. On the basis of end-users, the market has been classified as hospitals, clinics, ambulatory care, home care, and others. On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada. The European respiratory care devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The respiratory care devices market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The respiratory care devices market in the Middle East and Africa has been segmented into the Middle East and Africa. Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/respiratory-care-devices-market-6517 About Us: Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Contact Us: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune – 411028 Maharashtra, India Phone: +1 646 845 9312 Email: [email protected] Global Nebulizers Market forecast expected to hold a value of USD 1,629.7 Million by 2027 and is expected to register a growth of 7.32% from 2020 to 2027.
Nebulizers Market Synopsis Nebulizers are a device that has the capability of changing a medication from a liquid to a mist so that it can be inhaled into the lungs. High demand for respiratory devices, including nebulizers, due to the outbreak of COVID-19 globally, growing need for rescue medication, increasing prevalence of respiratory diseases, and rising demand for home healthcare devices are the key factors that are expected to drive the market growth. Moreover, the growing geriatric population, increasing consumption of alcohol, tobacco, cigarettes, and other such products may lead to respiratory diseases, and the rising number of initiatives taken by the government as well as the private organizations are also expected to boost the market growth. Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/9586 The growth of the global nebulizers market can be contributed to the growing need for rescue medication, high demand for respiratory devices, including nebulizers, due to outbreak of COVID-19 globally, and increasing prevalence of chronic respiratory diseases. According to a press release from Icon Plc in April 2020, the demand for respiratory devices has enormously increased, due to the rising cases of COVID-19. Furthermore, the growing demand for home healthcare devices, rising geriatric population, increasing consumption of alcohol, tobacco, cigarettes, and other such products that might lead to respiratory diseases, are also expected to fuel the market growth during the forecast period. However, the loss of drug during nebulization procedures, availability of various substitutes for nebulizers, and side effects of nebulizer solutions are expected to restrain the growth of the global nebulizers market. Several market players such as OMRON Healthcare, Koninklijke Philips N.V., and B. Braun Melsungen AG, among others currently dominate the global nebulizers market. The key players are involved in awareness campaigns, product approvals, mergers, and strategic collaborations to strengthen their market positions. For instance, in April 2020, B. Braun Melsungen AG received the Food and Drugs Administration (FDA) emergency use authorization for using its infusion pumps with nebulizers to treat COVID-19 patients. Regional Analysis The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas region held the largest market in 2019, owing to the rising demand for respiratory diseases in the region. The nebulizers market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European nebulizers market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The nebulizers market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing incidence rate of respiratory diseases, the market in Asia-Pacific is expected to be the fastest-growing. The nebulizers market in the Middle East & Africa has been divided into the Middle East and Africa. Segmentation The Global Nebulizers Market has been Segmented Based on the Type, Usage, Portability, and End User. Based on the Type, the global nebulizers market has been segmented into mesh, jet, and ultrasonic. The mesh segment is further divided into active and passive. The jet segment is expected to hold the largest market share owing to its low cost as compared to other types of nebulizers. On the basis of usage, the market has been segmented into reusable and disposable. The disposable nebulizers are expected to hold a major market share owing to their growing popularity amongst the users. Based on the portability, the market has been segmented into tabletop and portable. The portable nebulizers market is expected to grow at the fastest CAGR owing to its ease and convenience of use. The market based on end-user has been segmented into hospitals & clinics, home care, and others. The hospitals and clinics segment is expected to hold the largest market share owing to the larger patient footfall in hospitals. Key Players Some of the key players in the global nebulizers market are OMRON Healthcare (Japan), Koninklijke Philips N.V. (Netherlands), PARI (US), Vectura Group plc (UK), Rossmax International Ltd (Taiwan), Briggs Healthcare (US), GF Health Products, Inc. (US), Beurer GmBH (Germany), Agilent Technologies, Inc. (US), Drive DeVilbiss Healthcare (US), Invacare Corporation (US), and B. Braun Melsungen AG (Germany). Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nebulizers-market-9586 Nephrectomy Treatment Market size is expected to register a CAGR of 4.80% and was valued at USD 4,470.17 Million in 2018.
Nephrectomy is a surgical procedure performed to remove the kidney or a part of it. Nephrectomy is of two types, namely, radical nephrectomy in which the entire kidney is removed and partial nephrectomy where a part of the kidney or the diseased tissues is removed as a process of the treatment. Most frequently, a nephrectomy is done to treat kidney cancer or to remove a noncancerous tumor during urological surgery. The demand for nephrectomy is increasing due to the increasing prevalence of kidney cancer and chronic kidney diseases, the rising number of laparoscopic nephrectomy procedures, and increasing awareness about organ (kidney) transplant. These factors are expected to fuel the growth of the global nephrectomy market. However, risks and complications of the nephrectomy surgery and high cost of the procedure are anticipated to hamper the market growth. Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5356 Market Dynamics Kidney cancer is a disease in which the healthy cells of one or both kidneys start proliferating in an uncontrolled manner and form lumps (called a tumor). In chronic kidney disease (CKD), also known as chronic renal disease, chronic renal failure, or chronic kidney failure, the problems are kidney-related that result to cause slow and progressive loss of kidney function over a period and eventually results in permanent kidney failure. The main causes of kidney diseases are diabetes and high blood pressure. For instance, the National Kidney Foundation, Inc. reported that chronic kidney disease (CKD) is one of the leading causes of death in the US and also stated that around 75% of kidney failure was caused due to diabetes and high blood pressure between 2014 and 2016. According to the World Health Organization 2018 fact sheet, 422 million people were reported to have diabetes in 2014 across the world. The increasing prevalence of diabetes is leading to cause kidney problems and is thus driving the nephrectomy market. Similarly, the awareness and demand for organ (kidney) transplant is likely to drive the market growth. According to the US Government Information on Organ Donation and Transplantation, 21,167 kidney transplants took place in 2018 in the US. Hence the demand for organ transplants is fueling the growth of the worldwide nephrectomy market. Segmentation The Global Nephrectomy Market has been divided based on procedure, indication, end-user, and region. The market, based on procedure, has been segregated into open nephrectomy, laparoscopic nephrectomy, and robot-assisted laparoscopic surgery. Based on indication, the nephrectomy market has been divided into kidney cancer and other kidney diseases. On the basis of end-user, it is bifurcated into hospitals & clinics, surgical centers, and others. Regional Analysis The Global Nephrectomy Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Rest of the World (RoW). The Americas are likely to dominate the global nephrectomy market. The increasing prevalence of kidney cancer in the region, high prevalence of chronic kidney diseases, and growing development in diagnostics would drive the growth of the nephrectomy market in this region. Moreover, according to the American Cancer Society, it is estimated that about 73,820 new cases of kidney cancer (44,120 in men and 29,700 in women) are likely to occur in 2019. Also, kidney cancer is among the ten most common cancers in both men and women. Hence, the market for nephrectomy is expected to grow in the Americas. Europe held a substantial share in the global nephrectomy market. This can be attributed to the increasing incidence and prevalence of cancer, and public policies & reimbursement procedures in this region are expected to boost the growth of the market in this region. Asia-Pacific is estimated to be the fastest-growing region in the global market. This is due to the increasing R&D funding by developing countries and the development of the healthcare sector. The nephrectomy market in Rest of the World is expected to witness steady growth during the review period due to limited access and healthcare affordability among the population. Key Players The Prominent Players in the Global Nephrectomy Market are KARL STORZ SE & Co. KG (Germany)., Olympus Corporation (Japan), Medtronic Plc (Ireland), B. Braun Melsungen AG (Germany), Johnson & Johnson Services Inc. (US), Cook Group (US), CONMED Corporation (US), and XCELLANCE Medical Technologies (India). Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nephrectomy-market-5356 Drug of Abuse Testing Services Market is likely to register a CAGR of 7.77% and is projected to reach USD 6,673.3 Million by 2025. Drug of abuse testing is based on diagnosing drug addiction, also called substance use disorder, requiring a thorough evaluation and often includes an assessment by a psychiatrist, a psychologist, or a licensed alcohol and drug counselor. Blood, urine, or other lab tests are used to assess drug use, but they’re not a diagnostic test for addiction. These tests may be used for monitoring treatment.
Several factors such as increased use of drug testing at an organizational level, growing production and trade of illicit drugs worldwide, rise in road accidents and death rates, and the rise in the consumption of illegal drugs are driving the growth of the market. However, the inability of testing products to detect low-dose designer drugs, social issues associated with drug abuse testing, and legalization of drugs are a threat to the growth of the market. Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1930 Market Dynamics Drug testing in the workplace has traditionally been conducted using collection and analysis of urine. Urine as a specimen for drug testing allows for a long window of detection. Drug of abuse testing has been increasingly used by the American and European organizations at various levels like pre-employment screening, random drug/alcohol screening, post-incident drug or alcohol screening, and abstinence monitoring. Testing has become mandatory for multiple national and international organizations such as the International Olympic Committee (IOC), International Sports Federation (ISF) and National Olympic Committee, to stop drug abuse in sports. Thus, the market is projected to grow at a steady rate during the forecast period. Segmentation Based on the type of test, the global drug of abuse testing market has been segmented into onsite screening test and laboratory drug testing. The onsite screening test segment held a market share of 71.62% in 2018. Based on the sample, the global drug of abuse testing market has been segmented into by urine, saliva, hair, and others. Key Players The Major Players in the Global Drug Of Abuse Testing Market are Quest Diagnostics (US), Laboratory Corporation of America Holdings (LabCorp) (US), Abbott Laboratories (US), Randox laboratories (UK), Bio-Rad Laboratories, Inc. (the US), Sonic Healthcare (Australia), F. Hoffmann-La Roche Ltd (Switzerland), and Thermo Fisher Scientific, Inc. (US). Some of the key strategies followed by the players operating in the global drug of abuse testing market were mergers, acquisitions, and new product launches. Regional Analysis The Global Drug of Abuse Testing Market, on the basis of region, is divided into North America, Europe, Asia-Pacific, and the rest of the world. The North American region is projected to dominate the global drug of abuse testing market. The growth is mainly attributable to the increasing use of illicit drugs in the region. In order to reduce the cases of drug abuse, the US government has been taking various initiatives like mandatory drug testing in multiple departments including defense, oil, and gas, mining and department of transportation (DOT). Drug testing has also been made a mandatory process in educational institutions. The European market for drug of abuse testing is projected to be the second-largest during the forecast period. The broad market size of the region is a result of government initiatives to curb abuse and increasing alcohol-related accidents in the region, which leads to a greater emphasis on the use of testing equipment. Asia-Pacific is the fastest-growing market for drug of abuse testing. This owes to the rise in alcohol consumption and strict government rules and regulations about testing drug consumption in the region. The rest of the world is expected to grow at a steady rate due to the increasing awareness created by public and private organizations. Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/drug-abuse-testing-market-1930 The Global Mastitis Market growth is expected to register a CAGR of 15.07% to reach USD 18,338.80 Million till 2023. Mastitis is an infection in the tissue of one or both mammary glands inside the breast. It usually affects women who are breastfeeding, and it results from a blocked or a plugged duct. In bovine, mastitis is the inflammation of the mammary gland and udder tissue due to bacterial invasion of the teat canal by a variety of bacterial sources present on the farm, and can also occur as a result of chemical, mechanical, or thermal injury to the cow’s udder.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5379 The rising cases of breast cancer, increasing rate of pregnancy, and unhygienic barn conditions causing contagious mastitis in bovines across the globe is expected to enhance the market growth. However, the lack of awareness and complications in diagnosis due to similar symptoms of breast cancer & mastitis are projected to curb the growth of the market. Market Dynamics Mastitis has been gaining significance in recent years, owing to the rising incidence of breast cancer. For instance, the Breast Cancer Research Foundation estimated that 266,120 new cases of invasive breast cancer were diagnosed in women in 2018 in the US. Similarly, the UK witnessed around 11,563 deaths due to breast cancer in 2016, according to the Cancer Research UK. Whereas, according to the World Cancer Research Fund International, Belgium had the highest rate of breast cancer in women in 2017. Such a vast population suffering from breast cancer boosts market growth during the forecast period. Segmentation The global mastitis market, by type, has been segmented into bovine and human. Based on treatment, the Mastitis market has been categorized as bovine and human. Based on end user, the mastitis market has been classified as veterinary centers and hospital & clinics. Regional Analysis The global mastitis market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold the largest share of the global mastitis market. North America is expected to dominate the market, mainly due to the increasing p prevalence of mastitis among the bovine population and increasing incidence of breast cancer in the region. Europe is expected to account for the second-largest market share during the forecast period. The factors responsible for market growth in this region are advanced treatment facilities, rising government initiatives to promote healthy breastfeeding, and growing healthcare expenditure. For instance, according to Eurostat, Germany spent over EUR 321 billion in 2014. Asia-Pacific is estimated to be the fastest-growing region in the global market due to the presence of rapidly developing economies such as China, India, and South Korea. Moreover, the vast patient pool of chronic diseases and government initiatives of healthcare reforms will support the growth of the market. The mastitis market in the Middle East & Africa is expected to grow due to the affordability and accessibility of healthcare. Key Players The prominent players in the global Mastitis market are Bayer AG (Germany), Oncothyreon Inc (US), OncoGenex (US), Apthera Inc. (UK), Zoetis Inc. (US), Boehringer Ingelheim GmbH (Germany), Merck Co. & Inc. (US), Astellas Pharma Inc. (Japan), Pfizer Inc. (US), Novartis AG (Switzerland), Sanofi SA (France), and F. Hoffmann-La Roche AG (Switzerland). Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mastitis-market-5379 The Global MRSA Drugs Market analysis by MRFR expected the industry to register a CAGR of 4.4% to reach USD 4,312.2 million till 2023. Methicillin-resistant staphylococcus aureus (MRSA) is an infection caused by antibiotic-resistant strains of the pathogen. This infection is generally associated with invasive procedures such as surgeries, intravenous tubing, and sometimes through the skin to skin contact. MRSA drugs are used to kill or restrain methicillin-resistant staphylococcus aureus infection.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/2102 The increase in the prevalence of MRSA infections and number of hospitals, growing awareness about a bacterial infection, and increase in immuno-compromised population are expected to enhance the market growth. However, the high cost of novel MRSA drugs and hospital readmissions reduction program is projected to curb the growth of the market. Market Dynamics MRSA drugs have been gaining significant growth in recent years owing to the rising awareness about MRSA infections. For instance, October is celebrated as world MRSA awareness month and November 18, is celebrated as antibiotic awareness day in Europe to raise awareness of antibiotic resistance and promote the judicious use of antibiotics. Thus, the growing awareness about the cause and treatment related to bacterial infection among the population led to an increased usage of MRSA drug market, which thereby provides a favorable scenario for the market to grow during the forecast period. Segmentation The global MRSA drugs market, by drug class, has been segmented into sulfa drugs, tetracyclines, oxazolidinones, folate antagonists, lipopeptide, glycopeptide antibiotics, and others. Based on MRSA types, the MRSA drugs market has been categorized as hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA). By disease indication, the market is divided into skin infections, bone and joint infections, and bacteremia, and animal infections. Based on end user, the MRSA Drugs market has been categorized as hospitals and clinics, research and academic institutes, and others. Regional Analysis The global MRSA drugs market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold the largest share of the global MRSA drugs market. This is owing to the presence of key market players, well-developed healthcare infrastructure, in the US and Canada. Canada held 25% in North America MRSA Drugs market in 2016. Europe holds the second position in global MRSA drugs market due to the increasing research & development in the healthcare industry, availability of funds for research, rising cases of bacterial infection, and increasing adoption of novel drugs for the treatment of MRSA. Asia-Pacific is projected to be the fastest-growing region in the global market due to the rapidly developing medical industry, the presence of a huge patient pool, and increasing expenditure in healthcare by the government. China held a share of 25.1% in the Asia-Pacific MRSA drugs market in 2016. The Middle East & Africa holds the least market share in the global MRSA drugs market. Key Players The prominent players in the global MRSA drugs market are Merck KGaA (UK), Olon (Italy), Allergan (Dublin, Ireland), Baxter (US), Theravance Biopharma (Theravance Biopharma), Pfizer (US), Mylan NV (US), and Novartis (Switzerland). Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/mrsa-drugs-market-2102 |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
June 2021
Categories |